Photo: Depositphotos
Sep 23, 2025, 06:44
Therapeutic Plasma Exchange in Guillain-Barré Syndrome: ASFA 2023 Guidelines
Dr. Sumyea Kabir, Assistant Professor of Transfusion Medicine at BSMMU, shared a post on LinkedIn:
“Therapeutic Plasma Exchange (TPE) in Guillain-Barré Syndrome (GBS) – ASFA 2023 Snapshot
GBS is an Acute immune attack on peripheral nerves. ASFA 2023 places TPE as Category I, first-line therapy, equivalent to IVIG (but not combined).
Why it Works:
- TPE clears auto-antibodies and complement, helping nerves recover faster.
Protocol:
- ~1–1.5 plasma volumes per session
- 4–6 exchanges over 7–14 days
- Best started within the first week of symptoms.
Frontline Insight:
- I assisted in 7 GBS cases in My Residency Time at Bangladesh Medical University where, remarkably, after the first TPE session some patients regained limb movement and could sit upright. Early action truly saves function.
Monitor for Hypotension, Citrate-related Hypocalcemia, Bleeding risk, and central-line infection.
Reference: ASFA 9th Edition, 2023․”
Find more posts on Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals
Sep 29, 2025, 12:54
Sep 29, 2025, 12:33
Sep 29, 2025, 06:23
Sep 29, 2025, 05:06
Sep 29, 2025, 04:28